Uzmanlarımız
Flavio Guzmán, M.D.
Editor & CEO
Psychopharmacology Institute
Biyografi
Biyografi bulunamadı.
Flavio Guzmán, M.D. Yayınları
Q1 2026 Değerlendirmesi: Milsaperidone, GLP-1 RA’lar ve Zuranolone
0,50 SKP
Why did the FDA approve milsaperidone if it offers no clinical advantage over iloperidone? What does the FDA's removal of the GLP-1 suicidality warning mean for your practice? How does ACOG's updated guidance position zuranolone for severe postpartum depression?
Flavio Guzmán, M.D.
Psychopharmacology Institute
Daha fazla bilgi görüntüle
Venlafaksin Rehberi: Farmakoloji, Endikasyonlar, Dozlama Kılavuzları ve Advers Etkiler
0,50 SKP
This guide covers pharmacodynamics, pharmacokinetics, dosage forms, indications, side effects, and use in special populations. It also discusses venlafaxine's mechanism of action, metabolism, and FDA-approved and off-label uses.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Daha fazla bilgi görüntüle
Sitalopram ve Essitalopram: Temel Farklılıklar ve Benzerlikler Özeti
0,50 SKP
This article provides an in-depth comparison of citalopram and escitalopram, covering their chemical composition, pharmacokinetics, FDA-approved indications, off-label uses, potential side effects, and the risk of QT prolongation associated with both drugs. Furthermore, it addresses crucial considerations for prescribing these medications to specific patient populations.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Daha fazla bilgi görüntüle
Fluoksetin Pratik Rehberi: Farmakoloji, Endikasyonlar, Dozlama Kılavuzları ve Advers Etkiler
0,50 SKP
Fluoxetine is a potent serotonin reuptake inhibitor with a long half-life. It is FDA-approved for depression, OCD, panic disorder and bulimia. Fluoxetine also has off-label uses like treating repetitive behaviors in autism. This guide covers fluoxetine's pharmacology, dosing, side effects and use in special populations.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Daha fazla bilgi görüntüle
Fluvoxamine Pratik Rehberi: Farmakoloji, Endikasyonlar, Dozlama Kılavuzları ve Yan Etkiler
0,50 SKP
Fluvoxamine (Luvox) is approved for OCD in both pediatric and adult patients in the U.S. There is no definitive evidence suggesting it is more effective than other SSRIs for OCD. It is also approved for depression in the UK. Fluvoxamine is an inhibitor of CYP1A2 and should not be combined with MAOIs.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Daha fazla bilgi görüntüle
